Change of Director’s Interest Notices
August 11, 2020
Imagion Biosystems has announced the following Change of Director’s Interest Notices. Read them at ASX: Robert Proulx Michael Harsh Mark Van Asten Jovanka Naumoska Dianne
Category: Investor updates
Appendix 3G — Director’s Options
August 6, 2020
Imagion Biosystems has announced Appendix 3G — FY20 Director’s Options. Download the announcement.
Appendix 3G — Performance Rights and Performance Options
August 6, 2020
Imagion Biosystems has announced Appendix 3G — FY20 Performance Rights and Performance Options. Download the announcement.
Phase I Study Update: Submission for Ethics Approval Filed
August 5, 2020
Imagion Biosystems is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense® product for
Appendix 2A — IBXOA Options
August 4, 2020
Imagion Biosystems Limited announces Appendix 2A — IBXOA Options. Read the announcement.
Appendix 2A — Fully Paid Ordinary Shares
August 4, 2020
Imagion Biosystems Limited announces Appendix 2A — Fully Paid Ordinary Shares. Read the announcement.
Proposed Issue of Securities — IBXOA
August 4, 2020
Imagion Biosystems Limited announces the proposed issue of 1,500,000 options expiring 28 April, 2023. Read the announcement.
Proposed Issue of Securities — IBX
August 4, 2020
Imagion Biosystems Limited announces the proposed issue of 1,000,000 ordinary fully paid securities. Read the announcement.
Upcoming Release of Shares from Escrow
July 31, 2020
Imagion Biosystems Limited (ASX: IBX) (the Company) advises in accordance with Listing Rule 3.10A, that 2,500,000 Fully Paid Ordinary Shares will be released from voluntary
Quarterly Activity Report and Appendix C
July 29, 2020
Quarterly Activity Report – Period ending 30 June 2020 Q2 Highlights: Company announces plans for the Phase I first-in-human study to be undertaken in Australia